Published on 2 Nov 2023 on GuruFocus.com via Yahoo Finance
BridgeBio Pharma Inc (BBIO) Reports Q3 2023 Financial Results
BridgeBio Pharma Inc (NASDAQ:BBIO) reported Q3 2023 revenue of $4.1 million, compared to $0.3 million in Q3 2022.The company ended Q3 2023 with $522 million in cash, cash equivalents, and short-term restricted cash.BBIO raised approximately $316 million through an at-the-market (ATM) facility and a private placement equity financing (PIPE).Key programs such as acoramidis, infigratinib, BBP-418, and encaleret continue to progress, with positive results and regulatory meetings.
Warning! GuruFocus has detected 6 Warning Signs with BBIO.